Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06953089 · ClinicalTrials.gov registry record · Phase 2

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Phase 2 study of Solid Tumors, sponsored by DualityBio.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Phase 2
Development phase: 492
Enrollment target: 20
Study locations

NCT06953089: Recruiting Phase 2 study of Solid Tumors, sponsored by DualityBio.

NCT06953089 is a Phase 2 study of Solid Tumors that is actively recruiting participants, run by DualityBio. The registered enrollment target is 492 participants, above the 281-participant average among 125 other Solid Tumors trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06953089, a Phase 2 study of Solid Tumors, is actively recruiting participants, sponsored by DualityBio.

RECRUITING
Registry status: Phase 2
Development phase: 492 participants
Enrollment target: 20
Study locations

Study Summary

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Conditions Studied

Solid Tumors

Interventions

DRUG DB-1305/BNT325
DRUG BNT327
DRUG DB-1311/BNT324

Study Locations (20)

California

USA06-0 - Los Angeles
USA16-0 - Los Angeles

Texas

USA13-0 - Anderson
USA12-0 - Houston

Washington

USA09-0 - Puyallup
USA07-0 - Spokane

Queensland

AUS06-0 - Benowa
AUS04-0 - Birtinya

Colorado

USA01-0 - Wheat Ridge

Florida

USA08-0 - Florida City

Georgia

USA10-0 - Atlanta

Maryland

USA11-0 - Bethesda

Trial Details

Field	Value
Enrollment Target	492 participants
Start Date	2025-07-18
Est. Completion	2030-06-30
Phase	Phase 2

DualityBio

10 total trials

What NCT06953089 shows while recruiting

NCT06953089 is an interventional study that assigns participants to a tested intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap, above the 281-participant average among 125 other Solid Tumors trials with a reported enrollment target (75% higher).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which DB-1305/BNT325 is the first listed.

NCT06953089 names 20 study sites across 16 states, led by California, Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT06953089 about?

NCT06953089 is a clinical study titled "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors". A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

What is the current status of trial NCT06953089?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 492 participants. The study started on 2025-07-18. Estimated completion is 2030-06-30.

What conditions does trial NCT06953089 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT06953089?

The interventions under investigation include: DB-1305/BNT325 (DRUG), BNT327 (DRUG), DB-1311/BNT324 (DRUG).

Who is sponsoring clinical trial NCT06953089?

This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06953089 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06953089's enrollment target sits among peer trials

492 9th of 125 higher than 117 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06953089, the US trial registry maintained by the National Library of Medicine. NCT06953089 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.